192-LB: Temporal Relationship of New Pediatric Diabetes Diagnoses and COVID-19

SARS-CoV-2 infection may increase the incidence of diabetes mellitus (DM) in children.1-3 Mechanisms are incompletely understood and likely vary between type 1 and type 2 DM. All children may be at greater risk regardless of infection due to pandemic control measures increasing sedentary time and disrupting primary care.4,5 This cross sectional analysis examined the percentage of new DM diagnoses in children across 60-day calendar-time intervals relative to SARS-CoV-2 infection in a nationwide database, the National COVID Cohort Collaborative. The percentage of new type 1 and 2 DM diagnoses was highest in the acute period, within 60 days of infection. After acute infection, the percentage of new diagnoses appears lower than pre-infection percentages. Further study of this nuanced relationship is needed to inform screening and treatment. Disclosure N. Reddy: None. J. Harper: None. S. Johnson: None. R. A. Moffitt: None. M. Evans: None. H. Yeh: None. J. E. B. Reusch: Advisory Panel; Medtronic. R. Wong: None. J. B. Buse: Consultant; Alkahest, Anji Pharmaceuticals, AstraZeneca, Bayer Inc., Biomea Fusion, Inc., Boehringer Ingelheim International GmbH, CeQur SA, Cirius Therapeutics, Inc., Corcept Therapeutics, Eli Lilly and Company, GentiBio, Glycadia, Glyscend Inc., Janssen Pharmaceuticals, Inc., Mellitus Health, Pendulum Therapeutics, Praetego, LLC, Stability Health, Terns, Inc, Valo, Other Relationship; Novo Nordisk, Research Support; Dexcom, Inc., Novo Nordisk, vTv Therapeutics, Stock/Shareholder; Glyscend Inc., Mellitus Health, Pendulum Therapeutics, PhaseBio Pharmaceuticals, Inc., Praetego, LLC, Stability Health. C. Bramante: None. Funding National Center for Advancing Translational Sciences (U24TR002306); Clinical and Translational Science Institute, University of Minnesota (UL1TR002494); National Institute of Diabetes and Digestive and Kidney Diseases (K23DK124654); National Institutes of Health (3R01DK130351-02S1)